Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial

Abstract Background Due to the lack of effective treatment options, the prognosis of patients with relapsed/refractory acute myeloid leukemia (R/R AML) remains poor. Although chimeric antigen receptor (CAR)-T-cell therapy has shown promising effects in acute lymphoblastic leukemia (ALL) and lymphoma...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ruihao Huang, Xiaoqi Wang, Hongju Yan, Xu Tan, Yingying Ma, Maihong Wang, Xiao Han, Jia Liu, Li Gao, Lei Gao, Guangjun Jing, Cheng Zhang, Qin Wen, Xi Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-01-01
Edice:	Experimental Hematology & Oncology
Témata:	CAR-NK R/R AML CD33
On-line přístup:	https://doi.org/10.1186/s40164-024-00592-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!